Breast cancer

Jeffrey S. Ross; Gerald P. Linette; James Stec; Edward Clark; Mark Ayers; Fraser Symmans; Gabriel N. Hortobagyi; Lajos Pusztai

doi:10.1007/978-0-387-33227-7_24

Breast cancer

Jeffrey S. Ross, Gerald P. Linette, James Stec, Edward Clark, Mark Ayers, Fraser Symmans, Gabriel N. Hortobagyi, Lajos Pusztai

Pathology, Anatomical

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Based on current incidence rates, an American woman has a 1 in 9 chance of developing breast cancer at some time during her life.1 According to the American Cancer Societ Assistant y, in 2001, there were 192,200 new cases of invasive breast cancer and 47,100 cases of in situ disease in the United Profe States. That same year 40,200 American women died of the disease. This chapter considers the molecular pathology of breast cancer, focusing on the biomarker assays that are currently used in clinical management of the disease, excluding discussion of serum diagnostics, genetic predisposition testing, microarray-based RNA expression profiling, and micrometastasis detection, which are covered elsewhere in this book. The chapter concludes with a brief section on potential future assays, including the emerging field of pharmacogenomics.

Original language	English (US)
Title of host publication	Molecular Pathology in Clinical Practice
Publisher	Springer New York
Pages	269-278
Number of pages	10
ISBN (Print)	038733226X, 9780387332260
DOIs	https://doi.org/10.1007/978-0-387-33227-7_24
State	Published - 2007

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-0-387-33227-7_24

Cite this

@inbook{34f4744cc2204e888cd1e44fb634da09,

title = "Breast cancer",

abstract = "Based on current incidence rates, an American woman has a 1 in 9 chance of developing breast cancer at some time during her life.1 According to the American Cancer Societ Assistant y, in 2001, there were 192,200 new cases of invasive breast cancer and 47,100 cases of in situ disease in the United Profe States. That same year 40,200 American women died of the disease. This chapter considers the molecular pathology of breast cancer, focusing on the biomarker assays that are currently used in clinical management of the disease, excluding discussion of serum diagnostics, genetic predisposition testing, microarray-based RNA expression profiling, and micrometastasis detection, which are covered elsewhere in this book. The chapter concludes with a brief section on potential future assays, including the emerging field of pharmacogenomics.",

author = "Ross, {Jeffrey S.} and Linette, {Gerald P.} and James Stec and Edward Clark and Mark Ayers and Fraser Symmans and Hortobagyi, {Gabriel N.} and Lajos Pusztai",

year = "2007",

doi = "10.1007/978-0-387-33227-7_24",

language = "English (US)",

isbn = "038733226X",

pages = "269--278",

booktitle = "Molecular Pathology in Clinical Practice",

publisher = "Springer New York",

}

TY - CHAP

T1 - Breast cancer

AU - Ross, Jeffrey S.

AU - Linette, Gerald P.

AU - Stec, James

AU - Clark, Edward

AU - Ayers, Mark

AU - Symmans, Fraser

AU - Hortobagyi, Gabriel N.

AU - Pusztai, Lajos

PY - 2007

Y1 - 2007

N2 - Based on current incidence rates, an American woman has a 1 in 9 chance of developing breast cancer at some time during her life.1 According to the American Cancer Societ Assistant y, in 2001, there were 192,200 new cases of invasive breast cancer and 47,100 cases of in situ disease in the United Profe States. That same year 40,200 American women died of the disease. This chapter considers the molecular pathology of breast cancer, focusing on the biomarker assays that are currently used in clinical management of the disease, excluding discussion of serum diagnostics, genetic predisposition testing, microarray-based RNA expression profiling, and micrometastasis detection, which are covered elsewhere in this book. The chapter concludes with a brief section on potential future assays, including the emerging field of pharmacogenomics.

AB - Based on current incidence rates, an American woman has a 1 in 9 chance of developing breast cancer at some time during her life.1 According to the American Cancer Societ Assistant y, in 2001, there were 192,200 new cases of invasive breast cancer and 47,100 cases of in situ disease in the United Profe States. That same year 40,200 American women died of the disease. This chapter considers the molecular pathology of breast cancer, focusing on the biomarker assays that are currently used in clinical management of the disease, excluding discussion of serum diagnostics, genetic predisposition testing, microarray-based RNA expression profiling, and micrometastasis detection, which are covered elsewhere in this book. The chapter concludes with a brief section on potential future assays, including the emerging field of pharmacogenomics.

UR - http://www.scopus.com/inward/record.url?scp=84890000537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890000537&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-33227-7_24

DO - 10.1007/978-0-387-33227-7_24

M3 - Chapter

AN - SCOPUS:84890000537

SN - 038733226X

SN - 9780387332260

SP - 269

EP - 278

BT - Molecular Pathology in Clinical Practice

PB - Springer New York

ER -

Breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this